Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 12 points (0.1%) at 15,069 as of Wednesday, May 8, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,670 issues advancing vs. 1,254 declining with 121 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the sector include Shire ( SHPG), up 2.6%, Grifols ( GRFS), up 2.5%, Sanofi ( SNY), up 2.1%, Medtronic ( MDT), up 0.8% and Celgene Corporation ( CELG), up 0.7%. A company within the sector that fell today was Gilead ( GILD), up 1.28. TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today: 5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Care sector higher today. As of noon trading, DaVita HealthCare Partners is up $10.16 (8.64) to $127.72 on heavy volume Thus far, 1.8 million shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 823,500 shares. The stock has ranged in price between $120.52-$129.48 after having opened the day at $120.52 as compared to the previous trading day's close of $117.56. DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $12.5 billion and is part of the health services industry. The company has a P/E ratio of 21.6, above the S&P 500 P/E ratio of 17.7. Shares are up 6.5% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.